CN Patent

CN109803684B — 用于治疗肝细胞癌的组合疗法

Assigned to Sanitary Material R&d Management Co ltd · Expires 2022-08-23 · 4y expired

What this patent protects

本文提供了一种可用于治疗肝细胞癌和/或肝内胆管细胞癌的组合疗法。所述组合包括FGFR4抑制剂和CDK 4/6抑制剂。

USPTO Abstract

本文提供了一种可用于治疗肝细胞癌和/或肝内胆管细胞癌的组合疗法。所述组合包括FGFR4抑制剂和CDK 4/6抑制剂。

Drugs covered by this patent

trilaciclib-dihydrochloride (TRILACICLIB DIHYDROCHLORIDE)

Patent Metadata

Patent number: CN109803684B
Jurisdiction: CN
Classification: —
Expires: 2022-08-23
Drug substance claim: No
Drug product claim: No
Assignee: Sanitary Material R&d Management Co ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.